Aravis

Hedera-22 is a company focused on advancing the development of a DNA-based synthesis platform aimed at improving the production of new molecules through targeted genetic modifications. It specializes in computational analysis of biological data and employs in-house bioinformatics prediction technologies to enhance the identification of natural products. By integrating strategies from environmental microbiology and bioinformatics, Hedera-22 provides innovative solutions to the healthcare sector, enabling more effective and predictive approaches to molecular development and analysis.

Athelas, Inc., founded in 2002 and based in Mountain View, California, develops and manufactures portable blood analysis devices designed for at-home use. The company's technology focuses on monitoring chronically ill patients by providing diagnostic reports from a drop of blood, helping to identify conditions such as leukemia, infections, and inflammatory diseases early. Athelas has deployed an FDA-cleared blood diagnostic device along with other sensors to manage various health metrics including Blood Pressure, Weight, Glucose, and Medication Adherence. The company operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, with a research facility in Shanghai, China. The company specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions, including rheumatoid arthritis, metabolic diseases, fibrosis, and nonalcoholic steatohepatitis. Bird Rock Bio's technology focuses on creating highly selective monoclonal antibodies targeting specific members of the G-protein coupled receptor (GPCR) family, a class of proteins critical for therapeutic efficacy. Its lead product, RYI-008, is a potent monoclonal antibody targeting IL-6, a cytokine linked to inflammation and cancer. The company is dedicated to meeting the medical needs of patients in China while also aiming for global impact. Bird Rock Bio has a growing pipeline of therapeutic antibodies developed through proprietary technologies that ensure specificity and effectiveness in treatment.

Synaffix BV is a clinical-stage biotechnology company based in Oss, the Netherlands, focused on developing advanced antibody-drug conjugate (ADC) technology platforms for oncology. Established in 2010, the company specializes in technologies that enhance the efficacy and tolerability of ADCs. Its flagship offering, GlycoConnect, utilizes enzymatic modification of naturally occurring glycan anchor points on antibodies to enable efficient, site-specific, and stable conjugation of potent anti-cancer agents. Additionally, Synaffix provides HydraSpace, a linker technology designed to improve payload solubility and reduce aggregation potential. The company's portfolio also includes a metal-free click chemistry approach applicable across pharmaceutical and academic sectors. With a strong patent portfolio, Synaffix ensures protection for its innovations through at least 2035, positioning itself as a key player in the development of proprietary ADCs from a wide range of antibodies.

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company dedicated to developing innovative treatments for cardiopulmonary diseases. Headquartered in Warren, New Jersey, the company focuses on its proprietary INOpulse platform, which delivers pulsatile nitric oxide, targeting various forms of pulmonary hypertension. Bellerophon is advancing multiple product candidates through clinical trials, including treatments for pulmonary hypertension associated with interstitial lung disease and chronic obstructive pulmonary disease, as well as other conditions such as sarcoidosis and chronic thromboembolic pulmonary hypertension. Additionally, Bellerophon is exploring a bioabsorbable cardiac matrix device aimed at preventing cardiac remodeling after myocardial infarction, currently undergoing a feasibility clinical trial in the European Union. Founded in 2009 and previously known as Ikaria Development LLC, Bellerophon Therapeutics aims to address significant unmet medical needs in the cardiopulmonary space.

Telormedix is a biopharmaceutical company dedicated to advancing targeted immunity through the modulation of the innate immune system for the treatment of cancer and autoimmune diseases. The company develops innovative biopharmaceutical drugs that aim to address both cancer and infectious diseases. Its drug formulations incorporate clinically active small molecule compounds known for their favorable safety profiles and specific immunotherapeutic targets. This approach enables Telormedix to offer advanced treatment options that enhance medical outcomes for cancer patients.

Telormedix is a biopharmaceutical company dedicated to advancing targeted immunity through the modulation of the innate immune system for the treatment of cancer and autoimmune diseases. The company develops innovative biopharmaceutical drugs that aim to address both cancer and infectious diseases. Its drug formulations incorporate clinically active small molecule compounds known for their favorable safety profiles and specific immunotherapeutic targets. This approach enables Telormedix to offer advanced treatment options that enhance medical outcomes for cancer patients.

Synosia Therapeutics is a privately-owned company focused on developing and commercializing products aimed at addressing unmet medical needs in psychiatry and neurology. The company has a pipeline that includes six clinical-stage compounds, which have been acquired through strategic partnerships with major pharmaceutical firms such as Novartis, Roche, and Syngenta. Among these compounds, two are already marketed drugs that are being evaluated for new therapeutic indications to expand their application in treating neurological and psychiatric conditions, including anxiety and Parkinson's disease. In addition to its drug development efforts, Synosia Therapeutics also offers clinical development programs and research services.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, with a research facility in Shanghai, China. The company specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions, including rheumatoid arthritis, metabolic diseases, fibrosis, and nonalcoholic steatohepatitis. Bird Rock Bio's technology focuses on creating highly selective monoclonal antibodies targeting specific members of the G-protein coupled receptor (GPCR) family, a class of proteins critical for therapeutic efficacy. Its lead product, RYI-008, is a potent monoclonal antibody targeting IL-6, a cytokine linked to inflammation and cancer. The company is dedicated to meeting the medical needs of patients in China while also aiming for global impact. Bird Rock Bio has a growing pipeline of therapeutic antibodies developed through proprietary technologies that ensure specificity and effectiveness in treatment.

NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the development of engineered precision biologics through an expanded genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, facilitating the creation of next-generation therapeutics. Ambrx focuses on various product candidates, including antibody drug conjugates (ADCs), bispecific antibodies, targeted immuno-oncology treatments, and long-acting therapeutic peptides aimed at addressing metabolic and cardiovascular diseases. The company has a robust development pipeline featuring multiple clinical and preclinical programs, with its lead candidate ARX788 among them. Ambrx also collaborates with other organizations, such as MabSpace Biosciences and BeiGene, to enhance its research and development efforts in oncology and other therapeutic areas. Founded in 2003, Ambrx is committed to advancing the efficacy and safety of new biologic therapies for patients.

Synosia Therapeutics is a privately-owned company focused on developing and commercializing products aimed at addressing unmet medical needs in psychiatry and neurology. The company has a pipeline that includes six clinical-stage compounds, which have been acquired through strategic partnerships with major pharmaceutical firms such as Novartis, Roche, and Syngenta. Among these compounds, two are already marketed drugs that are being evaluated for new therapeutic indications to expand their application in treating neurological and psychiatric conditions, including anxiety and Parkinson's disease. In addition to its drug development efforts, Synosia Therapeutics also offers clinical development programs and research services.

S*BIO Pte, Ltd., a biotech company, focuses on the discovery and clinical development of novel targeted small drugs for the treatment of cancer. It serves the biotechnology industry in Singapore. The company was founded in 2000 and is based in Singapore, Singapore. S*BIO Pte, Ltd. operates as a subsidiary of Chiron Corporation Limited.

Telormedix is a biopharmaceutical company dedicated to advancing targeted immunity through the modulation of the innate immune system for the treatment of cancer and autoimmune diseases. The company develops innovative biopharmaceutical drugs that aim to address both cancer and infectious diseases. Its drug formulations incorporate clinically active small molecule compounds known for their favorable safety profiles and specific immunotherapeutic targets. This approach enables Telormedix to offer advanced treatment options that enhance medical outcomes for cancer patients.

ImVisioN Therapeutics is pioneering ILIT, a proprietary technology for the delivery of immunotherapy in the treatment of allergies. ILIT is clinically proven and has been shown to be a safer, more effective means of delivering allergy therapeutics. By applying another technology called modular antigen transporter (MAT), ImVisioN leverages the potential of ILIT to develop drugs that use allergens safely for specific and highly effective antigen presentation. In addition to the company’s lead product for the treatment of cat dander allergy, it also has programs addressing birch pollen and house dust mite allergies.

Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. The company offers OMIDRIA, a product used during cataract surgery in the United States. Omeros is advancing several clinical programs, including narsoplimab, which is in Phase III trials for conditions such as hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other key programs include OMS405, targeting opioid and nicotine addiction, and OMS527, aimed at treating addiction and movement disorders. The company's preclinical pipeline includes compounds addressing various conditions, such as paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Founded in 1994, Omeros is dedicated to addressing both large-market and orphan indications through innovative therapeutic approaches.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the development of engineered precision biologics through an expanded genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, facilitating the creation of next-generation therapeutics. Ambrx focuses on various product candidates, including antibody drug conjugates (ADCs), bispecific antibodies, targeted immuno-oncology treatments, and long-acting therapeutic peptides aimed at addressing metabolic and cardiovascular diseases. The company has a robust development pipeline featuring multiple clinical and preclinical programs, with its lead candidate ARX788 among them. Ambrx also collaborates with other organizations, such as MabSpace Biosciences and BeiGene, to enhance its research and development efforts in oncology and other therapeutic areas. Founded in 2003, Ambrx is committed to advancing the efficacy and safety of new biologic therapies for patients.

NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.

Ikaria is an integrated critical care company that develops and delivers innovative therapeutics and interventions for critically ill patients. The company focuses on creating and commercializing advanced therapies specifically designed to address the unique and complex medical needs of this vulnerable population. By aiming to be an indispensable partner to clinicians, Ikaria seeks to enhance patient care at critical moments, ensuring that healthcare providers have access to the necessary tools and support for effective treatment.

Borean Pharma ApS operates as a drug discovery and development company. The company's technology platform enables to design, develop, and produce pharmaceutical protein products. The company focuses on recombinant protein technology, as well as on antibody biopharmaceuticals. It offers protein products, antibody analogues, and CTLD library, as well as TNF antagonist for rheumatoid arthritis. The company was founded in 1997 and is based in Aarhus, Denmark.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

Miikana Therapeutics is a privately held biotechnology company dedicated to the discovery and development of innovative medicines for cancer treatment. The company engages in internal drug discovery programs and also in-licenses pre-clinical and early clinical oncology drug candidates, aiming to enhance its therapeutic offerings. Through its focused approach, Miikana Therapeutics strives to advance potential treatments that address the complex challenges of cancer care.

Nura, Inc. is focused on discovering and developing pharmaceuticals aimed at treating neurodegenerative diseases and behavioral disorders. The company specializes in therapeutics that target G Protein-coupled receptors (GPCR) and phosphodiesterase (PDE) enzymes expressed in the brain. Nura’s research includes programs for conditions such as Parkinson's disease, Alzheimer's disease, schizophrenia, depression, anxiety, obesity, and addiction, as well as attention-deficit hyperactivity disorder and pain. Through its innovative approach, Nura aims to address significant unmet medical needs in these areas.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Kalypsys specializes in pathway-based drug discovery and development services. The company conducts discovery programs across a wide range of therapeutic areas, leveraging its automated and integrated suite of technologies in biology, chemistry, and informatics. By utilizing advanced methodologies, Kalypsys aims to enhance the efficiency and effectiveness of the drug discovery process, ultimately contributing to the development of innovative therapies.

Miikana Therapeutics is a privately held biotechnology company dedicated to the discovery and development of innovative medicines for cancer treatment. The company engages in internal drug discovery programs and also in-licenses pre-clinical and early clinical oncology drug candidates, aiming to enhance its therapeutic offerings. Through its focused approach, Miikana Therapeutics strives to advance potential treatments that address the complex challenges of cancer care.